The FDA approved Signos’ glucose monitoring system for weight loss, offering a new option for Americans to manage their weight. Obesity drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound can be hard to access due to costs and coverage limitations. Signos uses AI and CGM technology to provide personalized data and lifestyle recommendations for weight management.

Signos’ system aims to help the 74% of overweight or obese Americans manage their weight and reduce the $170 billion obesity epidemic cost to the U.S. healthcare system. Customers can purchase a membership for $139 (3-month plan) or $129 (6-month plan) with CGMs shipped based on the chosen plan. The company is working to get insurance coverage for the system for weight management.

The Signos system can be used in combination with GLP-1s or bariatric surgery for weight management. CGMs track glucose levels and send data wirelessly to the Signos app, where users can log food intake and exercise. The system helps users understand their body’s response to food and exercise and make behavioral changes for long-term weight management.

Signos has not disclosed the number of current users, but tens of thousands have tried the system. The company has increased its inventory and software capacity to handle increased demand following FDA approval. Signos aims to help users at any point in their weight loss journey, whether they have a few pounds or a significant amount to lose.

Read more at CNBC: FDA approves Signos glucose monitoring for weight loss